Topic Review
Three-Dimensional Bioprinting in Cardiovascular Disease
Three-dimensional (3D) printing plays an important role in cardiovascular disease through the use of personalised models that replicate the normal anatomy and its pathology with high accuracy and reliability. 3D bioprinting represents a promising field that could revolutionise the future of cardiovascular disease treatment. Three-dimensional bioprinting uses mostly the same additive manufacturing technologies but prints functional living structures from biological components such as living cells, biomaterials and growth factors.
  • 245
  • 01 Aug 2023
Topic Review
Novel Fucoidan Pharmaceutical Formulations and Their Potential Application
Fucoidan belongs to a family of sulfated, L-fucose-rich polysaccharides found in the cell wall matrix of various species of marine brown algae (Phaeophyta: Laminariaceae, Fucaceae, Chordariaceae and Alariaceae). Fucoidan can also be obtained from sea cucumbers (Holothuroidea: Stichopodidae, Holothuriidae), sea urchin eggs (Echinoidea: Strongylocentrotidae, Arbaciidae) and sea grasses (Cymodoceaceae).
  • 339
  • 01 Aug 2023
Topic Review
Effects of AntagomiRs on Different Lung Diseases
MiRNAs have been shown to play a crucial role among lung cancer, pulmonary fibrosis, tuberculosis (TBC) infection, and bronchial hypersensitivity, thus including chronic obstructive pulmonary disease (COPD) and asthma. The oncogenic effect of several miRNAs has been ruled out. In order to act on miRNAs turnover, antagomiRs have been developed.
  • 247
  • 01 Aug 2023
Topic Review
IL-33/IL-31 Axis in Autoimmune Disorders
Several allergic and immunologic diseases including asthma, food allergy (FA), chronic spontaneous urticaria (CSU), atopic dermatitis (AD), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Behçet’s disease (BD) are characterized by the involvement of Th2 immunity. Several mediators lead to immunoglobulin (Ig)E production, thus including key cytokines such as interleukin (IL)-4, IL-5, and IL-13. Among them, IL-31 and IL-33 have been recently studied as novel biomarkers and future therapeutic targets for allergic and immunological disorders. IL-31 is a proinflammatory cytokine—it regulates cell proliferation and is involved in tissue remodeling. IL-33, acting through its receptor suppression of tumorigenity (ST2L), is an alarmin cytokine from the IL-1 family, whose expression is mediated by tissue damage. The latter has a pleiotropic effect, as it may modulate specific and innate immune cells functions.
  • 273
  • 01 Aug 2023
Topic Review
Alarmins in Pathogenesis and Progression of Multiple Myeloma
Multiple Myeloma (MM) is a haematological disease resulting from the neoplastic transformation of plasma cells. The uncontrolled growth of plasma cells in the bone marrow and the delivery of several cytokines causes bone erosion that often does not regress, even in the event of disease remission. MM is characterised by a multi-step evolutionary path, which starts with an early asymptomatic stage defined as monoclonal gammopathy of undetermined significance (MGUS) evolving to overt disease.
  • 290
  • 01 Aug 2023
Topic Review
Transmembrane Protease Serine 2 in Prostate Cancer
The abundant expression of TMPRSS2 is evident in normal prostatic tissue. Different endogenous substrates of TMRPSS2 have been identified, including the epithelial sodium channel (ENaC) the protease-activated receptor-2 (PAR-2), as well as other serine protease-like zymogens, such as kallikrein-2 (KLK2), suggesting its potential contribution to prostate homeostasis and its plausible involvement in male fertility. The TMPRSS2:ERG fusion is considered relevant to prostate cancer, but its association with the development and progression as well as its clinical significance have not been fully elucidated. 
  • 254
  • 01 Aug 2023
Topic Review
Technologies to Detect and Monitor Atrial Fibrillation
Up to 20% of patients with ischemic stroke or transient ischemic attack have a prior history of known atrial fibrillation (AF). Additionally, unknown AF can be detected by different monitoring strategies in up to 23% of patients with cryptogenic or non-cardioembolic stroke. However, most studies had substantial gaps in monitoring time, especially early after the index event. Following this, AF rates would be higher if patients underwent continuous monitoring early after stroke, avoiding any gaps in monitoring. The few existing randomized studies focused on patients with cryptogenic stroke but did not focus otherwise specifically on prevention strategies in patients at high risk for AF (patients at higher age or with high CHA2DS2-VASC scores). Besides invasive implantable loop recorders (ILRs), external loop recorders (ELRs) and mobile cardiac outpatient telemetry (MCOT) are non-invasive tools that are commonly used for long-term ECG monitoring in cryptogenic-stroke patients in the ambulatory setting. 
  • 469
  • 01 Aug 2023
Topic Review
Mechanisms of Skin Aging Processes
With the advancement of living standards in modern society and the emergence of an aging population, an increasing number of people are becoming interested in the topic of aging and anti-aging. An important feature of aging is skin aging, and women are particularly concerned about skin aging. In the field of cosmetics, the market share of anti-aging products is increasing year by year.
  • 293
  • 01 Aug 2023
Topic Review
Interplay between Osteoporosis and the Mediterranean Diet
Diet is a modifiable factor in bone and muscle health. The Mediterranean diet (MedDiet) is rich in nutrients and contains key bioactive components with probable protective effects on muscle and bone deterioration. Osteoporosis (OP) is disease that increase frailty and susceptibility to fracture, morbidity and mortality. Therefore, it is necessary to combat them in the population. In this regard, MedDiet adherence has proven to be beneficial to bone mineral density (BMD), muscle mass, physical function, OP and sarcopenia. Hence, this diet is proposed as a therapeutic tool that could slow the onset of osteoporosis.
  • 214
  • 01 Aug 2023
Topic Review
Capmatinib in Treatment of Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a leading cause of death. Capmatinib is a Type Ib MET Tyrosine Kinase Inhibitor (TKI) first discovered in 2011 and was Food and Drug Administration (FDA) approved in August 2022 for advanced NSCLC with MET exon 14 skipping mutation. Clinical trials now involve combination therapy with capmatinib, including amivantamab, trametinib, and immunotherapy. Furthermore, new drug agents, particularly antibody–drug conjugates, are being developed to help treat patients with acquired resistance from capmatinib and other tyrosine kinase inhibitors (TKIs).
  • 311
  • 01 Aug 2023
  • Page
  • of
  • 1349
Video Production Service